News
-
-
-
-
PRESS RELEASE
Biotest AG increased sales by 32% in the financial year 2023
Biotest AG reported 32% increase in sales for FY 2023, reaching revenue of €684.6 million. EBIT forecast achieved at €143 million. Key developments include Yimmugo marketing authorization in the US and successful Phase III study with fibrinogen -
-
-
PRESS RELEASE
Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne and emphasises important contribution to patient care
Prof Dr Karl Lauterbach visits Biotest AG's plasma donation centre in Cologne, emphasizing vital contribution to patient care. Plasma donation in Germany crucial for medical supply -
-
PRESS RELEASE
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate
Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate. Study results confirm safety profile & effectiveness equal to standard care in reducing blood loss. Biotest aims to address global medical need with USD 800 million market potential -